/
DCF Valuation
Base-case fair value
$336.15
Intrinsic $448.20 · 25% MOS
Current price: $79.49
Base-case summary
Our base-case DCF for Ani Pharmaceuticals Inc (ANIP) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 201.7% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $191M in trailing free cash flow, this produces an intrinsic value of $448.20 per share. A 25% safety margin gives a fair value of $336.15, suggesting the stock is currently 323% undervalued against the $79.49 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$191M
Cash & equivalents
$311M
Total debt
$305M
Shares outstanding
22M